Hepatocellular carcinoma is the most common form of liver cancer. The risk of hepatocellular carcinoma, the most common type of liver cancer, is higher in patients with long-term liver diseases. It is a serious illness that can be life-threatening.
Learn more about a clinical trial for Heptocellular Carcinoma
Contact Research
The most common symptoms of GERD are acid indigestion and heartburn. Heartburn is normal. Frequent and problematic heartburn should be reviewed with your gastroenterologist.
Patients with severe gastroesophageal reflux disease (GERD) may experience complications such as damage to the esophagus, Barrett’s esophagus or esophageal cancer.
Find out more about clinical studies for patients with GERD.
Hepatitis C virus is most often transmitted through exposure to infected blood. Most people have no symptoms. Those who do develop symptoms may have fatigue, nausea, loss of appetite, and yellowing of the eyes and skin.
Hepatitis C is treated with antiviral medications. In some people, newer medicines can eradicate the virus.
Nonerosive reflux disease (NERD), a subcategory of GERD, is a heterogeneous disorder characterized by troublesome reflux-related symptoms in the absence of endoscopic evidence of esophageal mucosal erosions or breaks. Approximately 50-85% of patients with reflux-related symptoms that are accompanied by negative endoscopic findings are diagnosed with NERD. It is estimated that more than two-thirds of GERD patients have NERD.
The most common symptoms of esophagitis are heartburn, chest pain and dysphagia (trouble swallowing). If you have been diagnosed with or suspect you may have erosive esophagitis please contact us to learn more about current clinical trials.
A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients with Healed Erosive Esophagitis PROTOCOL NO. EE-301
The exact cause of Barrett’s esophagus is not fully understood, but long-term GERD is the number one risk factor. Not all people with GERD get Barrett’s esophagus – in fact, it develops in less than 10% of people with GERD. It is more common in people who have had GERD for a long time or who were diagnosed with it at a young age.
Learn more about clinical trials for the diagnosis and treatment of Barrett’s Esophagus.
LUCID DIAGNOSTICS PROTOCOL PR-0139 (EG-CL-101) A Multicenter, Single-Arm Study of the Efficacy of EsoGuard on Samples Collected Using EsoCheck versus Esophagogastroduodenoscopy for the Diagnosis of Barrett’s Esophagus in an At-Risk Screening Population
LUCID DIAGNOSTICS PROTOCOL PR-0138 (EG-CL-102) A Multicenter Case-Control Study of the Efficacy of EsoGuard on Samples Collected Using EsoCheck, versus Esophagogastroduodenoscopy, for the Diagnosis of Barrett’s Esophagus with and without Dysplasia, and for Esophageal Adenocarcinoma
No results.
Clinical trials look at new ways to prevent, detect or treat gastrointestinal diseases or conditions, while also providing valuable information about health and disease progress. Colonoscopy is the most important step in the prevention of colon cancer. Colonoscopy is the only colon cancer screening method that allows your gastroenterologist to visualize the entire colon and remove most polyps at the same time.
The most important step prior to your colonoscopy is cleaning out your colon. This will allow your physician to discover and remove polyps. Learn more about a new trial on colonoscopy prep.
Gastroparesis is a condition that affects the normal spontaneous movement of the muscles (motility) in your stomach causing food to stay in your stomach for longer than it should. Gastroparesis can cause a feeling of fullness, nausea and vomiting.
Encore Borland Groover Research is actively recruiting patient volunteer for a Gastroparesis study in Jacksonville.
ClinicalTrials.gov Study Details
Symptomatic Diabetic or Idiopathic Gastroparesis
Protocol Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of NG101 Administered Orally to Patients with Gastroparesis Protocol Number: NG101-201
Contact Research
Helicobacter pylori (H. pylori) is a type of bacteria.
Many researchers believe that H. pylori is responsible for the majority of peptic ulcers, chronic gastritis and increases the risk of developing gastric cancer.
Symptoms of H. pylori may include gnawing or burning pain, nausea, vomiting, or loss of appetite.
ClinicalTrials.gov Study Details
Helicobacter Pylori Infection
A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy with Oral Lansoprazole 30 mg Daily in Patients with Helicobacter Pylori Infection
Have you been diagnosed with Chronic Pancreatitis? We are currently working on a research study using an Investigational drug that is being evaluated to treat patients who have been diagnosed with Chronic Pancreatitis (CP). The purpose of this study (double‐blind phase) is to determine how well the Investigational drug works in controlling pain associated with this disease; determine the pharmacokinetics (PK) (drug levels of the Investigational drug); and how safe the drug is when taking three doses of NI‐03 (100 mg, 200 mg and 300 mg) when taken three times daily for 28 consecutive days (4 weeks) compared to placebo (sugar pill) also taken in the same manner.
Chronic Pancreatitis clinical trial now enrolling near you. See if you qualify today.
ClinicalTrials.gov Study Details
Chronic Pancreatitis
A phase 1, single dose pk and safety study with NI-03 followed by a phase 2, randomized, double-blind, parallel-group dose-ranging study to evaluated the safety and efficacy of NI-03 compared to placebo in subjects and efficacy of NI-03 compared to placebo in subjects with chronic pancreatitis
No results.
